Jazz Pharmaceuticals PLC to Host Investor Webcast to Review Phase 3 Idiopathic Hypersomnia Data Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : I was curious, you mentioned sleep inertia as a problem in idiopathic hypersomnia patients. Did you look at any measures of sleep inertia in this study? And if so, is there anything you can say about that?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Great. And on the percentage of patients who discontinued during the open-label titration period, can you talk about that, how that compares to other benchmarks with patients initiating Xyrem, for example?

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : I have a couple. First, what is the forum for -- the next forum for you to present some of these -- the answers that you're deferring today? Is there a logical near-term forum for that?

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Okay. Then when one asks KOLs what they create IH patients with, they often say sodium oxybate already. Is it your view that many of these patients can't get oxybate covered by payers and that an approval of the indication will fundamentally change prescription demand or filling of prescriptions? Or do you think it's more of a play of underdiagnosis and your need to educate sort of put more into the funnel at the time?

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : And one last one, Dan. Is there anything you'd like to say about the interplay of Xyrem and Xywav prescribing so far year-to-date as it relates to net revenue? Or is that for the call?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : I just want to come back to those 37,000 diagnosed patients now. Granted that there's no approved treatment, how many or what percentage of that 37,000 remain under sort of disposition care where you have overlap? And how much work do you have to do to drive those diagnosed patients back to that physician office? Or are they -- have they remained under that care?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : The portion of current Xyrem use for IH, could you quantify that at all? And if it's changed over time? Because I have heard mixed things from physicians in terms of access to Xyrem for IH. And then just will the current Xywav sales force be sufficient when you get the IH indication or whether you look to add to that, given the overlap and the conditions in terms of the target physician audience?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : Okay. And then just a quick follow-up. Will you look to get a pediatric IH indication at some point? It seems like this is more of a younger population. But would it make sense to go down that far, maybe also to help with exclusivity down the road?